Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
UnitedHealthcareMedicaid · Prior Auth · Medical Benefit Drug Policy · Genetics, Endocrinology, Pediatrics +1 moreMedium impact

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)

Effective date
Dec 1, 2026
Identified
Nov 7, 2026

Summary

UnitedHealthcare Community Plan published a new Medicaid medical benefit drug policy for Genglycos (pariglasgene brecaparvovec-opnr) for glycogen storage disease type Ia, effective 2026-12-01. Coverage requires the patient to be at least 8 years old, have a confirmed diagnosis with G6PC bi-allelic variants or absent G6Pase activity on liver biopsy, be on cornstarch therapy, lack detectable AAV8 antibodies, have no prior gene therapy for GSDIa, and be prescribed by or with a metabolic specialist; authorization is limited to one lifetime treatment for up to 45 days from approval.

Get alerts when payers change rules like this one

We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.

Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01By 2026-12-01: Billing team and providers should confirm that any Genglycos request for a Community Plan Medicaid member is supported by chart notes and lab documentation showing the G6PC variants or liver biopsy result, current cornstarch therapy, AAV8 antibody status, prior gene therapy history, and metabolic specialist involvement before scheduling administration.
02Front desk staff should flag planned inpatient admissions requested solely for Genglycos infusion, since the policy excludes them, and charge entry should follow the FDA-approved dosing labeling.
03Track the 45-day authorization window from approval in the prior auth tracker so the infusion is scheduled within it; requests that do not meet these criteria will not be approved under this policy.

Original notice

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)
uhcprovider.com · Always check the source before changing claims.
View original ↗

Related changes

See all UnitedHealthcare changes →
Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)LowEffective Dec 1, 2026 · Medical Benefit Drug PolicyBrowse every UnitedHealthcare change in the policy list

Related policy hubs

UnitedHealthcare policiesGeneticsEndocrinologyPediatricsPharmacy

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account